Scientific and Ethical Issues in Mitochondrial Donation by Craven L et al.
 
 
 
 
 
Newcastle University ePrints | eprint.ncl.ac.uk 
Craven L, Murphy J, Turnbull DM, Taylor RW, Gorman GS, McFarland 
R. Scientific and Ethical Issues in Mitochondrial Donation. New 
Bioethics 2018, 24(1), 57-73.
DOI link 
https://doi.org/10.1080/20502877.2018.1440725  
ePrints link 
http://eprint.ncl.ac.uk/247166  
Date deposited 
03/04/2018 
Copyright 
© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis 
Group This is an Open Access article distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which 
permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited. 
Licence 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ynbi20
The New Bioethics
A Multidisciplinary Journal of Biotechnology and the Body
ISSN: 2050-2877 (Print) 2050-2885 (Online) Journal homepage: http://www.tandfonline.com/loi/ynbi20
Scientific and Ethical Issues in Mitochondrial
Donation
Lyndsey Craven, Julie Murphy, Doug M. Turnbull, Robert W. Taylor, Grainne
S. Gorman & Robert McFarland
To cite this article: Lyndsey Craven, Julie Murphy, Doug M. Turnbull, Robert W. Taylor, Grainne
S. Gorman & Robert McFarland (2018) Scientific and Ethical Issues in Mitochondrial Donation, The
New Bioethics, 24:1, 57-73, DOI: 10.1080/20502877.2018.1440725
To link to this article:  https://doi.org/10.1080/20502877.2018.1440725
© 2018 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group
Published online: 12 Mar 2018.
Submit your article to this journal 
Article views: 132
View related articles 
View Crossmark data
Citing articles: 1 View citing articles 
Scientific and Ethical Issues in
Mitochondrial Donation
Lyndsey Craven, Julie Murphy, Doug M. Turnbull,
Robert W. Taylor, Grainne S. Gorman,
Robert McFarland
Wellcome Centre for Mitochondrial Research, Institute of Neuroscience,
Newcastle University, Newcastle upon Tyne, UK
The development of any novel reproductive technology involving manipulation
of human embryos is almost inevitably going to be controversial and evoke sin-
cerely held, but diametrically opposing views. The plethora of scientific, ethical
and legal issues that surround the clinical use of such techniques fuels this diver-
gence of opinion. During the policy change that was required to allow the use of
mitochondrial donation in the UK, many of these issues were intensely scruti-
nised by a variety of people and in multiple contexts. This extensive process
resulted in the publication of several reports that informed the recommen-
dations made to government. We have been intrinsically involved in the devel-
opment of mitochondrial donation, from refining the basic technique for use in
human embryos through to clinical service delivery, and have taken the oppor-
tunity in this article to offer our own perspective on the issues it raises.
keywords mitochondrial donation, ethics, human embryo, oocytes,
maternal spindle transfer, pronuclear transfer
1. Introduction
Mitochondrial disease is a term that encompasses a diverse group of genetic dis-
orders characterised by mitochondrial dysfunction. These disorders show vast clini-
cal heterogeneity, with patients presenting at any age and with a wide range of
clinical features often affecting multiple organ systems (Gorman et al. 2016). The
symptoms are usually progressive and can be associated with severe morbidity
and early mortality. Inherited mitochondrial disease is genetically heterogeneous
and can be caused by a number of different genetic mutations found in either the
nuclear DNA, which is inherited from both parents, or the mitochondrial DNA
(mtDNA), which is inherited from the mother only. This has made the clinical
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diagnosis of mitochondrial disease challenging. Recent advances in next-generation
sequencing technology have significantly improved the diagnostic rate for both
patients and their families (Craven et al. 2017a) but unfortunately, progress in
this area has not been matched with the development of effective treatments.
There is currently no cure for mitochondrial disease and clinical management is
focussed on symptom alleviation. This highlights the importance of obtaining a
genetic diagnosis as it opens up the possibility of genetic counselling to understand
the risks of transmitting mitochondrial disease and allows reproductive options to
be considered that will reduce this risk.
The clinical variability of mitochondrial DNA (mtDNA) disease caused by patho-
genic mutations in the mitochondrial genome is partly explained by the unique fea-
tures of mitochondrial genetics (Craven et al. 2017a). One such feature is the
multicopy nature of the mitochondrial genome, meaning that individual human
cells can contain from 100 to more than 100,000 copies of mtDNA. In patients
who carry a pathogenic mtDNA mutation, this mutation can be present in all
copies of the mitochondrial genome (termed homoplasmy) or only a proportion of
the genomes (termed heteroplasmy). When heteroplasmy exists, it is the ratio of wild-
type to mutant mtDNA that is important and clinical features will only manifest once
a critical threshold level has been exceeded. This is complicated further by the presence
of a ‘genetic bottleneck’ during development of the female germline, which means that
women who carry a pathogenic mtDNA mutation can transmit different levels of
mutant mtDNA to their children (Figure 1). This makes genetic counselling difficult
figure 1. The mitochondrial genetic bottleneck, heteroplasmy and the threshold effect.
Note: In patients who carry a pathogenic mtDNA mutation, the mutation can be present in
all copies of the mitochondrial genome (homoplasmy) or only a proportion of the
genomes (heteroplasmy). When heteroplasmy exists, it is the ratio of wild-type to mutant
mtDNA that is important and clinical features will only manifest once a critical threshold
level has been exceeded. The presence of a genetic bottleneck during early development
means that women who carry a pathogenic mtDNA mutation can transmit different levels
of the mutant mtDNA to their children.
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as it is not always possible to predict the risk of disease in the child. Moreover, an
asymptomatic woman carrying low levels of mutant mtDNA could have a child
who is severely affected by mitochondrial disease.
There are a number of reproductive options currently available for women who
carry a pathogenic mtDNA mutation and wish to reduce the risk of having a child
severely affected by mitochondrial disease. The complexity of mitochondrial gen-
etics, and the fact that not every reproductive option will be suitable for every
woman, requires that both mitochondrial and fertility specialists provide advice
to couples before an informed decision is made to proceed with a particular
option. For those couples wanting a child whose genetic constitution will be inher-
ited from both parents, reproductive options can include becoming pregnant
without medical intervention, prenatal testing and preimplantation genetic diagno-
sis. Importantly, these options will be suitable for women who produce eggs with
lower levels of mutant mtDNA but will not reduce the risk of mtDNA disease if
a woman produces eggs that contain only high levels of the mutation. Alternate
options, which include adoption or egg donation, prevent transmission of
mtDNA disease and completely remove the risk of having an affected child. The
child will not be genetically related to both parents, however, which may be a con-
sideration for some. More recently, mitochondrial donation has become an
additional option that may be suitable for a select group of patients deemed to be
at risk of transmitting a serious mtDNA disease and for which PGD will be unsui-
table (Gorman et al. 2015). Importantly, no alternative reproductive options exist
that allow such women to have a genetically related child, demonstrating a need
for mitochondrial donation. At the same time, this does not detract from the
other reproductive options that are currently available and aims to provide more
reproductive choice. Some have claimed that this assigns too much value to
genetic relatedness and assumes that a genetic connection between a mother and
her child is essential. A counter argument might be posed that the decision to use
a certain reproductive option is a down to personal choice, and for some patients,
being genetically related to the child will influence this decision. To support this,
recent HFEA figures show that ∼5% of IVF cycles performed in the UK in 2014
used donor eggs.1 This implies that most couples opting for fertility treatment
choose to pursue a reproductive option that allows them to have a genetically
related child when such an option exists; this view is supported by feedback pro-
vided from our patient-based focus groups.
The process of mitochondrial donation involves removing the nuclear genome
from an oocyte (or zygote) that contains mutant mtDNA and transferring it to a
donor oocyte (or zygote) with wild-type mtDNA that has its own nuclear genome
removed (Figure 2). The reconstituted oocyte (or zygote) contains the nuclear
DNA from the intending parents and the mtDNA from a donor, meaning that the
resulting child will be genetically related to both parents but will have a much
lower risk of developing mtDNA disease. The combination of three people’s
DNA, namely the mother and father’s nuclear DNA and the donor’s mtDNA, led
1 https://www.hfea.gov.uk/about-us/news-and-press-releases/2016-news-and-press-releases/
new-report-shows-ivf-cycles-are-on-the-rise-but-few-involve-frozen-eggs/.
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to the alternate and nowwidely used term ‘three parent baby’. This term, coined and
often used by the media, is considered inaccurate and has resulted in misconceptions
around the technique. At the same time, it is a term that is known by many and has
increased awareness of mitochondrial disease, which can ultimately only benefit
patients and patient groups.
figure 2. Mitochondrial donation techniques. Mitochondrial donation involves removing
the nuclear genome from an oocyte (or zygote) that contains mutant mtDNA and transferring
it to a donor oocyte (or zygote) with wild-type mtDNA that has its own nuclear genome
removed. The reconstituted oocyte (or zygote) contains the nuclear DNA from the intending
parents and the mtDNA from a donor. Mitochondrial donation can be performed between
unfertilised human oocytes using a technique called (a) maternal spindle transfer (MST)
or between fertilised human zygotes using a technique called (b) pronuclear transfer (PNT).
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The development of any novel reproductive technology that involves the manipu-
lation of human embryos will always evoke strong opinions and controversy. This is
partly because of the plethora of scientific, ethical and legal issues that surround the
clinical use of such techniques. During the policy change that was required to allow
the use of mitochondrial donation in the UK, many of these issues were extensively
scrutinised by many different people in multiple contexts, resulting in the publi-
cation of numerous reports that informed recommendations made to government.
In this article, we discuss some of the issues that resonated given our involvement
in the development of mitochondrial donation from both a clinical and scientific
viewpoint.
2. The use of human embryos in research
The experimental techniques required to perform mitochondrial donation, or
nuclear transplantation as it was originally known, were first developed in mouse
embryos nearly 35 years ago (McGrath and Solter 1983). The original research
paper described a successful method for transferring nuclei between fertilised
mouse embryos, which allowed good embryo survival and the birth of live
animals. At this time, before the first reports of pathogenic mtDNA mutations
associated with disease (Holt et al. 1988; Wallace et al. 1988), the potential for
the technique to be used to prevent transmission of mtDNA disorders had not
been realised. The connection was made a number of years later, and interestingly,
one of the first reports that considered the use of nuclear transplantation to ‘cure
mitochondrial disease’ was published in a healthcare ethics journal (Rubenstein
et al. 1995).
Many research groups performed nuclear transplantation in mouse embryos to
address different biological questions (Meirelles and Smith 1997, 1998), but our
research group in Newcastle (UK) initially focussed on investigating the potential
of the technique to prevent transmission of mtDNA disease. Early studies in
mouse embryos went some way to show that the technique could in fact reduce
the risk of mtDNA disease (Sato et al. 2005), but disparities between mouse and
human embryos meant that the ability to relate these research findings directly to
the clinical application of mitochondrial donation was limited. Consequently, the
next stage of the research journey required the use of human embryos to determine
the safety and efficacy of the technique. This in itself could be considered controver-
sial and raises many ethical questions, the answers to which are complex and influ-
enced by personal views and beliefs.
The need to regulate the use of human embryos in both fertility treatment and
scientific research became apparent following the birth of the first in vitro fertilisa-
tion (IVF) baby in the UK. Not long after this monumental breakthrough, the
Warnock Committee was convened to consider the policies and safeguards that
should be applied in relation to human fertilisation and embryology, including dis-
cussions around whether or not human embryo research should be permitted. Much
of this debate focussed on the moral status of the embryo, which is beyond the scope
of this article, but is something that remains contentious, continuing to divide
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opinion across the spectrum of religious and secular beliefs. The inquiry, which was
published in the highly esteemed Warnock Report, recommended that research on
human embryos should be permitted, but with the restriction that such embryos
could only be used for up to 14 days after fertilisation. This rule, which was pro-
posed over 30 years ago, is only now being revisited following recent advances in
the in vitro culture of human embryos (Deglincerti et al. 2016) and has reignited
the ethical debate on embryo research (Cavaliere 2017). The Warnock Report
was subsequently used to provide a framework for legislation and formed the
basis of the Human Fertilisation and Embryology Act 1990 (HFE Act 1990). This
Act, which underwent a major review before publication of the HFE Act 2008, out-
lines purposes for which human embryos can be used in research. Such research is
under strict regulation in the UK by the Human Fertilisation and Embryology Auth-
ority (HFEA), who have the power to issue licenses for research projects that involve
human embryos. For a license to be granted, the HFEA must be satisfied that the use
of human embryos is necessary and that the research fulfils at least one of the pur-
poses outlined in the HFE Act.
The research purposes for which embryo research is permitted include the devel-
opment of treatments for serious disease or other serious medical conditions, and so
our team applied to the HFEA for a license to allow research into mitochondrial
donation as a novel IVF treatment to avoid transmission of mtDNA disease. Follow-
ing an extensive review of the scientific methodology and legal interpretation of the
original HFE Act 1990, which highlighted the incredible foresight of the Warnock
Committee some years earlier, the Newcastle team were granted the first research
licence allowing the use of human embryos to develop the techniques required to
perform mitochondrial donation. In the first instance, this was done using abnor-
mally fertilised human embryos often produced during a normal IVF cycle that
are unsuitable for clinical use and usually discarded. Importantly, these abnormal
embryos can only be used with informed consent from the couple undergoing the
IVF treatment following a detailed explanation of the research project.
Early experiments to develop the technique of mitochondrial donation using
abnormally fertilised human embryos necessitated many modifications to the meth-
odology used previously in mouse embryos, highlighting the absolute requirement
for human embryo research before clinical application can be considered. These
‘proof of principle’ experiments were crucial to demonstrate the potential for mito-
chondrial donation to prevent transmission of mtDNA disease (Craven et al. 2010)
but were restricted by the use of abnormally fertilised embryos. This was mainly
because abnormal embryos have a limited capacity for development, which makes
it difficult to evaluate both the safety and efficacy of the technique. For this
reason, the next stage of the research project required the use of normally fertilised
human embryos, which raises more ethical questions surrounding not only the use of
these embryos but also the source of the eggs and sperm needed to produce them.
The creation of human embryos for research purposes is allowed in the UK, one of
only a few countries that permit this by law. This regulatory position differs through-
out the world, with many countries having laws that reflect their own ethical, social
and religious frameworks. The creation of human embryos for research was one of
the recommendations proposed by the Warnock Committee, who advised that the
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fertilisation of donated eggs specifically for research purposes should be permissible
to avoid confining this research to ‘spare’ embryos (Warnock 1985). There were
several reasons why the committee believed this should be permitted, one being
that it would increase the validity of the research being undertaken, which would
turn out to be crucial for the evaluation of mitochondrial donation before its
future clinical application.
The majority of embryos used in research are donated by patients undergoing fer-
tility treatment.2 When the research requires the creation of embryos, the eggs can be
donated by those undergoing fertility treatment, or so-called ‘egg-sharers’. These are
women who donate half of the eggs collected during an IVF cycle for a reduction in
their treatment costs (private patients) or an extra IVF cycle if they fail to become
pregnant during the IVF cycles offered on the National Health Service (NHS).
Ethical concerns have been raised around human eggs being viewed as a commodity
and the potential exploitation of women taking part, but a study into the experiences
of women who participated in the scheme revealed that they found this not to be the
case (Haimes et al. 2012). Furthermore, a review of the outcomes of this scheme
revealed that it was successful for both egg sharers and researchers in terms of
achieving a pregnancy and allowing research to progress, which is often limited
by egg availability (Choudhary et al. 2012). The other source of human eggs for
the mitochondrial donation study is non-patient egg donors living in the North
East of England, who donate their eggs solely for this research project. This is a
very involved process requiring significant commitment and as such, it has been
deemed ethically acceptable to provide egg donors with appropriate financial com-
pensation for their time and inconvenience (Hyun 2011). Importantly, this compen-
sation is viewed as insufficient to be considered an inducement. The role of all egg
donors in the development of mitochondrial donation as an IVF treatment has
been pivotal and their contribution is duly acknowledged because without them,
it would not be possible to accurately assess the safety and efficacy of the technique
before clinical application.
The continuation of this research with normally fertilised human embryos
revealed that the mitochondrial donation technique had to be refined further. This
was because the methodology developed with abnormally fertilised human
embryos was not well tolerated by normal embryos, with reduced survival following
the procedure (Hyslop et al. 2016). This was attributed to accelerated embryo clea-
vage associated with developmental competence, meaning that the mitochondrial
donation technique was being performed too close to the first embryo division. To
address this, an alternative approach was developed whereby the procedure was per-
formed much sooner after fertilisation, resulting in improved embryo survival and
efficient development to the blastocyst stage, a prerequisite of any IVF treatment
being considered for clinical application. In addition, the blastocysts that developed
were used to derive embryonic stem cells, which could then be investigated to
provide further data regarding the safety of the technique. This analysis revealed
that the low level of mtDNA transferred to the donor embryo during the procedure
could increase over time in a limited number of stem cell lines, which led the authors
2 http://hfeaarchive.uksouth.cloudapp.azure.com/www.hfea.gov.uk/hfea/rss/161.html.
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to conclude that mitochondrial donation can potentially reduce but not completely
eradicate the risk of mtDNA disease and should be considered in combination with
prenatal testing. These important issues would not have been identified without the
preclinical research, highlighting the importance of using normally fertilised human
embryos in such experiments.
3. The use of unfertilised or fertilised human oocytes (MST vs PNT)
Mitochondrial donation can be performed at various stages of oocyte development
using unfertilised oocytes and techniques such as maternal spindle transfer (MST),
polar body transfer (PBT) or germinal vesicle transfer (GVT). Alternatively, it can
be performed using fertilised oocytes (zygotes) at the one-cell stage of development
and a technique known as pronuclear transfer (PNT) (Craven et al. 2017b). Both
MST and PNT are the most well studied mitochondrial donation techniques to
date (Figure 2), with more scientific research to support their clinical use over
PBTand GVT. This is reflected in the current UK legislation, namely the Human Fer-
tilisation and Embryology (Mitochondrial Donation) Regulations 2015, which
states that only eggs and embryos created followingMSTor PNT techniques are per-
mitted for clinical use. This ‘permission’ is defined in law and is the result of wide-
ranging discussion of the ethical issues around both mitochondrial donation tech-
niques. A consequence of the legal framework for application of these two tech-
niques in the UK is that their use is subject to strict regulatory supervision via the
HFEA who issue individual licences on a case by case basis submitted by approved
centres.
Although the basic principle of MSTand PNT is the same, and the procedures per-
formed only 6-8 hours apart in terms of the timing of preimplantation development,
a fundamental difference is that MST is performed using an unfertilised human
oocyte that is subsequently fertilised, whilst PNT is performed using two human
oocytes that are already fertilised. Consequently, the use of PNT as a clinical treat-
ment could raise more ethical concerns than MST because of the need to create fer-
tilised zygotes that are subsequently manipulated and discarded during the
treatment process. These ethical issues are often influenced by personal beliefs and
views on the moral status of the embryo, with some having the opinion that MST
is more ethically acceptable as it avoids creating an embryo that will ultimately be
destroyed. This is perhaps an over simplistic view, however, as it fails to take into
account the embryos that have been created and discarded during the crucial
research that has taken place to investigate MST as a potential mitochondrial
donation technique. Furthermore, although according to UK law a zygote at the pro-
nuclear stage is considered an embryo, this is not a universally accepted definition
because the genetic material in both pronuclei has not yet fused to form the
nucleus of the embryo. In much the same way, there is an argument that ‘new life’
has not been created until the pronuclei have fused and there has been an exchange
of genetic material between parental gametes. With this in mind, the ethical dilemma
of PNT may be less convincing and might be considered to have been overplayed. In
support of this, the Nuffield Council on Bioethics concluded that it would be ethical
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to use either MSTor PNT in the clinical application of mitochondrial donation and
that ongoing research into both techniques was important to establish which tech-
nique was likely to be the safest and most effective.3 This reflects a view expressed
throughout the debates on mitochondrial donation, that the preferred use of MSTor
PNT should not be dictated solely by ethics, which is heavily influenced by personal
views and opinions, but should consider the available safety and efficacy data for
each technique.
Given that there is currently no evidence to suggest that MST or PNT is prefer-
able in terms of safety,4 it is likely that the decision to use a particular technique
will ultimately depend on the expertise of the fertility clinic offering mitochondrial
donation. The views of the intending parents may also determine which technique
is used, which was reported in the first controversial case of a live birth using MST
to prevent transmission of mtDNA disease (Zhang et al. 2017). Here, the authors
state that the patient opted for MST over PNT for religious reasons to ‘avoid dis-
rupting a zygote’. However, as previously mentioned, although there may be no
‘disruption’ of a zygote during an individual MST procedure, the research that
refined (and continues to improve) this technique has required creation and
destruction of numerous human zygotes (Paull et al. 2012; Tachibana et al.
2012; Kang et al. 2016; Yamada et al. 2016). Furthermore, the embryos that
were produced in this clinical treatment were biopsied at the blastocyst stage,
which ultimately led to the destruction of those embryos that were found to be
genetically abnormal. This highlights another ethical conundrum involving other
reproductive options such as PGD, which has been used and widely accepted for
many years yet leads to the destruction of embryos deemed unsuitable for transfer
or cryopreservation. In this regard, mitochondrial donation could raise fewer
ethical concerns than PGD if it allowed the creation and subsequent destruction
of fewer embryos.5
4. Safety issues associated with mitochondrial donation
The safety of any new medical intervention, whether it be a new drug or novel treat-
ment, is paramount and must be adequately addressed before it can be used ethi-
cally in the clinic. The same is true for mitochondrial donation, emphasising the
importance of preclinical research to investigate the safety and effectiveness of
any novel reproductive technology (Dondorp and de Wert 2011). This is reflected
in the Nuffield Council on Bioethics report, which concluded that it would be
ethical for families to use mitochondrial donation techniques provided they are
proven to be acceptably safe and effective. This highlights that the ethical use of
any treatment is intrinsically linked to its safety, in that it would never be ethical
to electively offer a treatment for a non-essential indication (i.e. not life-saving)
that was known to be unsafe. Even when such a treatment is life-saving, the use
3 http://nuffieldbioethics.org/wpcontent/uploads/2014/06/Novel_techniques_for_the_prevention_of_mitochondrial_
DNA_disorders_compressed.pdf.
4 http://www.hfea.gov.uk/docs/Fourth_scientific_review_mitochondria_2016.PDF.
5 http://nuffieldbioethics.org/wpcontent/uploads/2014/06/Novel_techniques_for_the_prevention_of_mitochondrial_
DNA_disorders_compressed.pdf.
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of ‘unsafe’ treatments would be exceptional. The challenge is reaching a consensus
on the likely safety issues that may be applicable to the use of mitochondrial
donation and then deciding when an appropriate level of safety has been achieved
to allow the timely use of the technique in the clinic (Herbert and Turnbull 2018).
This arduous task was given to an independent panel of experts, convened by the
HFEA, who extensively reviewed the available scientific evidence around the
safety and effectiveness of mitochondrial donation on four separate occasions
over a period of six years (Greenfield et al. 2017). Their first three reports concluded
that there was no evidence to suggest that mitochondrial donation was unsafe for
clinical use but proposed additional experiments that would help support this con-
clusion. The most recent report, published in 2016, went further and declared both
MSTand PNT sufficiently safe to proceed cautiously with clinical application in the
UK under restricted circumstances (http://www.hfea.gov.uk/docs/Fourth_scientific_
review_mitochondria_2016.PDF). This is somewhat contentious, however, and
there are some who claim we still do not know enough about the safety implications
of mitochondrial donation to allow it to be offered in the clinic (Reinhardt et al.
2013).
One such safety issue that became apparent during the preclinical evaluation of
mitochondrial donation was the observation that an initial low level of ‘mtDNA car-
ryover’ transferred with the nuclear genome during the mitochondrial donation
process could progressively increase in a limited number of embryonic stem cell
lines derived from mitochondrial donation embryos (Hyslop et al. 2016; Kang
et al. 2016; Yamada et al. 2016). Although this could merely be a feature of stem
cell biology, which is possible given the differences between cultured stem cells
and post-implantation embryo development, it is obviously a concern as it implies
that in a small number of cases, the level of mutated mtDNA could increase
during pregnancy and result in a child severely affected by mtDNA disease. This
led researchers to conclude that mitochondrial donation has the potential to
reduce the risk of mtDNA disease but may not guarantee prevention (Hyslop
et al. 2016). For this reason, the expert panel recommended that all patients who
become pregnant following MST or PNT are offered prenatal testing. If this test
shows that the level of mutated mtDNA has increased, couples may consider termi-
nating the pregnancy. With this in mind, we were concerned about how our patients
would react to this research and whether it would change their opinion of the mito-
chondrial donation technique. To address this, we held a focus group with a small
number of patients and their families to inform them of the latest research findings
and discuss some of the important outcomes, including the possible risk that mito-
chondrial donation could result in a child affected by mtDNA disease. The overall
feeling was that couples would still consider using the technique despite being
aware of the limitations and risks.
This raises two important issues, the first being that it is not possible to know all
the potential risks of any new clinical treatment or medical intervention until it is
tried for the first time. Preclinical research can allude to potential risks, but the find-
ings may be considered speculative until clinical evaluation. As clinicians and scien-
tists, it is our responsibility to try and understand the available preclinical data and
discuss the potential risks with patients before they make an informed decision to
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proceed. This will involve considering the possible risk to benefit ratio, which is
something parents with children affected by mitochondrial disease may have to
do on a regular basis. What was poignant from the parliamentary debates around
mitochondrial donation was that many parents with children affected by mtDNA
disease talked about taking these risks every day, for example, by giving their
child many different drugs that often have not been approved for use in paediatric
patients, in an attempt to manage the symptoms of their mitochondrial disease.
We must give serious consideration and weight to such parental concerns in any
assessment of the risk-benefit of offering a technique that prevents the transmission
of serious mtDNA disease.
The second issue is the importance of introducing safeguards to protect patients
from possible risks until more is known about safety and efficacy of the technique.
In this regard, the expert panel made several recommendations, including that con-
sideration is given to ‘haplogroup matching’, a precautionary step that involves
selecting a mitochondrial donor with a similar mtDNA sequence to the patient
(http://www.hfea.gov.uk/docs/Fourth_scientific_review_mitochondria_2016.PDF).
It is noteworthy, however, that research studies which have proposed possible inter-
actions between the nucleus and the mtDNA have been performed using highly
inbred animal models that are very different to an outbred human population and
as such, the potential risks of nuclear-mitochondrial incompatibility are likely to
be low (Eyre-Walker 2017). Therefore, the need to haplogroup match may be
unnecessary and could limit use of the technique. A consultation on the clinical
use of mitochondrial donation in the USAwent one step further and recommended
that if clinical trials are permitted, they should consider allowing the transfer of only
male embryos following the procedure (http://www.nationalacademies.org/hmd/
Reports/2016/Mitochondrial-Replacement-Techniques.aspx). Given the maternal
inheritance of mtDNA, this would not constitute germ-line modification and
could be considered advantageous until more is known about any potential risks
associated with the procedure. This obviously has ethical implications and was
rejected in the UK for several reasons. One of these is that sex selection would
require additional embryo manipulation beyond that already performed during
the mitochondrial donation procedure, which could compromise embryo develop-
ment and limit the chance of a successful outcome. It would also immediately
reduce the number of embryos available for transfer by half (on average), which
would reduce the efficiency of the technique and could mean that patients must
undergo repeated treatment cycles.
Long term follow-up of any children born will be crucial to confirm the safety and
efficacy of mitochondrial donation. Patients and their families are encouraged to
take part in this follow-up and, through multiple focus groups, have been very
much involved in shaping the overall structure of this care pathway, from antenatal
checks during pregnancy right through to a detailed neurodevelopmental assessment
of the child at 18 months old. One major way in which patient focus groups influ-
enced the care pathway for children born following mitochondrial donation was in
relation to follow-up. It was quickly apparent that while parents were keen to take
part in follow-up, they were reluctant to ‘medicalise’ an otherwise healthy child and
so wanted to keep hospital visits to a minimum. Taking this into account, the
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follow-up pathway takes advantage of the multiple health professional encounters
that are routine for babies and young children in the UK NHS. Routine and a
small amount of additional information will be collected at these time points
embedded in the NHS health surveillance for all children and include neonatal hos-
pital discharge assessments, vaccinations and routine health visitor assessments.
One significant addition to the follow-up care pathway for children born after mito-
chondrial donation will be a detailed neurodevelopmental assessment at 18 months
old, a time point in development when all children would be expected to be walking
and talking. The outcome of this developmental follow-up study will inform the
HFEA and the general public on the longer-term safety of the technique. It is antici-
pated that children will continue to be seen by an expert in paediatric mitochondrial
disease, at parental request, until the age of 5 years, providing further long-term data
on the neurodevelopmental outcome.
5. Engagement and mitochondrial donation
Engaging the public, patients and policy makers in our research has been integral in
the development of mitochondrial donation as a clinical treatment. The purpose of
this engagement is not only to inform but also to stimulate debate. This was crucial
in the lead up to the parliamentary votes that took place on mitochondrial donation,
but is something we have continued to do to ensure our research remains
patient-focussed.
Before the government would consider changing the law to allow mitochondrial
donation in the UK, it was important to gauge public opinion of the technique. To do
this, the HFEA were asked to engage with the public and seek views on mitochon-
drial donation through a public dialogue launched in collaboration with Science-
wise. This extensive public consultation comprised many different project strands,
including open consultation meetings and deliberative public workshops. These
workshops required that participants attended two events, the first aimed at provid-
ing the background knowledge needed to engage in debates around mitochondrial
donation and the second focussed on identifying and debating the social and
ethical issues around the technique. The overall outcome of the consultation, used
by the HFEA to provide advice to government,6 was general support for permitting
mitochondrial donation in the UK. There were some strong ethical concerns
expressed during the consultation but the overall view was that the ethical concerns
were outweighed by the arguments in favour of permitting the technique. The con-
sultation was thoroughly evaluated and duly recognised as an exceptional case of
public engagement for policy purposes.7
We have continued to engage the public with issues surrounding mitochondrial
donation. This has involved addressing some of the complex science associated
with the technique, which was made more understandable by comparing
6 http://hfeaarchive.uksouth.cloudapp.azure.com/www.hfea.gov.uk/docs/Mitochondria_replacement_consultation_-_
advice_for_Government.pdf.
7 http://webarchive.nationalarchives.gov.uk/20170110134326/, http://www.sciencewise-erc.org.uk/cms/assets/Uploads/
Mitochondria-evaluation-FINAL-2013.pdf.
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mitochondria to the ‘batteries of the cell’. This analogy was criticised by some who
claimed that it was an oversimplification, but there are others who believe that effec-
tive communication to mass audiences should be simple and clear. Support for this is
provided by previous public health message over the last 30 years, such as communi-
cation around HIV, stroke or smoking, which have all used simple analogies to
convey a complex message.
The purpose of our patient engagement has been two-fold. In the first instance, it
was important to support the patients and their families who wished to engage with
the politicians who would ultimately vote on whether to allow mitochondrial
donation in the UK. This provided an opportunity for patients and patient organis-
ations to share their own personal experiences of mitochondrial disease, giving poli-
ticians access to knowledge traditionally sourced only from healthcare professionals
or scientists. Our engagement and communication strategy considered potential bar-
riers to engagement and to ensure inclusivity, incorporated many different formats
including guidance notes, patient newsletters, patient information days and
drop-in sessions. The success of this engagement, which also included patients
attending parliamentary briefing sessions and speaking openly with politicians
about the reality of mitochondrial disease, was apparent during the debates that
took place in the Houses of Parliament, with many MPs referring to patients or
families with whom they had met. This not only increased awareness of mitochon-
drial disease, but also empowered patients to actively participate and drive through
legislative change. This could partly explain why support for mitochondrial
donation was provided by many patients and families even if they would not directly
benefit from the technique or consider using it themselves.
Given their involvement in the policy engagement surrounding mitochondrial
donation, we have endeavoured to maintain a two-way dialogue with patients
and patient organisations that have been front and central in terms of their advocacy
for this technique. This allows research updates to be discussed, which ensures that
our research focus remains patient-driven, but also provides an opportunity to
inform patients about the reproductive options that are currently available. Not
all the reproductive options will be suitable to every woman who carries an
mtDNA mutation but making patients aware of them from early in reproductive
life is something we strive to do. There are benefits and drawbacks to all the repro-
ductive options and intending parents must ultimately decide, with advice from
specialists, which one is right for them. It is vital that this decision is well-informed
and for this reason, we have set up the Mitochondrial Reproductive Advice Clinic as
part of the innovative clinical service we offer in Newcastle. This clinic has a dual
purpose, the first being to discuss the available reproductive options with patients
and the second to assess fitness for pregnancy, which is obviously important when
the intending mother could be affected by mtDNA disease. The information pro-
vided in the clinic aims to convey complex mitochondrial genetics in a simple and
easy to understand way and there are several formats that have been employed to
do this, including the production of a short animation which clearly explains all
of the reproductive options available to couples. We have also put together ‘infor-
mation packs’ containing detailed, though carefully explained, information on the
different reproductive options and what each option entails. We feel this is
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important in patients giving informed consent and to some extent allays claims that
both the public debates and media coverage of mitochondrial donation presented
this as a ‘straightforward’ solution to help women with mtDNA mutations have a
healthy child (Herbrand 2017). The patient information we provide includes a com-
prehensive overview of each reproductive option with a detailed description of the
process required for any IVF-based treatment, with opportunities to discuss
further in the mitoART clinic for couples who wish to consider an IVF-based
option. This includes information on managing expectation; it is important to
inform couples that any IVF treatment can fail at any stage and there are no guar-
antees of a pregnancy. Consequently, it may be necessary for couples to undergo
several cycles of IVF before a pregnancy is achieved. The information we provide
has been reviewed by patients and patient organisations to ensure it is both clear
and relevant to the people who will access it and subsequently adapted based on
their feedback.
6. Conclusion
It has been proposed by some that the change in law to allow mitochondrial
donation in the UK was rushed and happened before the all scientific and ethical
issues around the technique had been fully explored. There are many who would
refute this claim by drawing attention to the fact that the issues have been discussed
and debated by many separate groups for nearly 18 years (Craven et al. 2016). Fur-
thermore, although the Mitochondrial Donation Regulations came into force in
March 2015, the technique is yet to be applied in the UK. This demonstrates the
importance placed on responsible innovation and governance of mitochondrial
donation, which should be applied to any other reproductive technologies that
become available in the future.
The use of mitochondrial donation to prevent the transmission of mtDNA disease
is allowed in the UK, the only country to have legislated in this area (Herbert and
Turnbull 2017). In reaching a decision to permit this technique, the scientific,
ethical and legal issues have been deliberated and importantly, continue to be delib-
erated to this day. A conclusion reached by many is that it is ethical to support and
promote the use of mitochondrial donation but with the view that it is used cau-
tiously and under strict regulation (Bredenoord and Appleby 2017). It must also
be noted that mitochondrial donation is only legal in the UK if the purpose is to
avoid serious mtDNA disease, with questions remaining around the ethical use of
the technique for alternative clinical applications, such as to help with infertility.
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